A Clinical Study of ONO-1110 in Patients With Hunner Type Interstitial Cystitis

Launched by ONO PHARMACEUTICAL CO. LTD · Dec 22, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a medication called ONO-1110 to see if it can help patients with Hunner Type Interstitial Cystitis (HIC), a condition that causes chronic pelvic pain and issues with urination. The trial is currently recruiting participants who are 18 years or older, of Japanese descent, and have been diagnosed with HIC through a procedure called cystoscopy. To participate, individuals should be able to understand the study requirements and keep track of their symptoms using diaries and questionnaires.

Participants in this study will be monitored for the effectiveness and safety of the medication. They will need to be outpatients, meaning they can live at home while taking part in the trial. However, certain people, such as those with specific bladder conditions or neurological diseases, may not qualify to ensure the study results are accurate. If you or someone you know is dealing with HIC and fits the eligibility criteria, this could be an opportunity to access a new treatment while contributing to medical research.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Japanese (both sexes)
• • Age (at the time of informed consent): 18 years and older
• • Outpatient
• • Patients who are considered capable of understanding the study procedures and completing the pain diary, bladder diary, and questionnaires appropriately by the investigator (sub-investigator）
• • Patients given a diagnosis of HIC by cystoscopy
• • Patients with chronic pelvic pain involving the bladder and lower urinary tract symptoms such as increased micturition and pollakiuria
• Exclusion Criteria:
• • Patients with a history and presence of chemical cystitis
• • Patients with a history of bladder augmentation or radical cystectomy
• • Patients with pain other than HIC that may affect assessments in this study
• • Patients with a past history of or concurrent neurologic diseases that may affect assessments in this study
• • Patients receiving medications for psychiatric disease